The products of a growing number of genes have been shown to display seemingly contradictory functions; namely, the induction of tumorigenesis and the induction of apoptosis. Heregulin's involvement in oncogenesis occurs through its interactions with members of the EGF receptor tyrosine kinase family. Recently one isoform of heregulin, b2b, was isolated in an in vitro screen for dominant, apoptosis-inducing genes in kidney epithelial cells. Here we show that heregulin is also capable of mediating apoptosis in human and murine mammary tumor cell lines and murine tumors. Furthermore, through transfection of the human breast cancer cell line MCF-7 with the truncated transmembrane/cytoplasmic segment of the heregulin gene, we show that the intracellular region of the heregulin precursor is sucient for induction of apoptosis. Through the use of DNA fragmentation assays we also show that apoptosis occurs in cell lines established from heregulin-induced mammary gland tumors. TdT addition of digoxigenin labeled nucleotides to 3' OH ends of DNA breaks recapitulated these results in the actual tumors. Finally, over-expression of heregulin is shown to lead to the down-regulation of Bcl-2, an inhibitor of apoptosis. Conversely, the transfection of Bcl-2 into MCF-7 cells inhibits heregulin-mediated programmed cell death.
Introduction
Neu dierentiation factor (NDF), heregulin (HRG), glial growth factors (GGFs) and acetylcholine receptor inducing activity (ARIA) are all spliced isoforms of a single gene, NRG1 (Holmes et al., 1992; Wen et al., 1992; Marchionni et al., 1993; Falls et al., 1993) . Recently two related genes, NRG2 and NRG3, have also been identi®ed (Carraway et al., 1997; Zhang et al., 1997) . This family of ligands are known collectively as neuregulins and interact with the EGF receptor family. Their primary binding occurs with ErbB3 or ErbB4 and leads to receptor homodimerization or heterodimerization with ErbB2, receptor phosphorylation and subsequent interaction with various SH2 proteins (Carraway et al., 1994; Plowman et al., 1993; Peles et al., 1991) .
Much interest in the heregulin family is based on the fact that the receptors for these ligands are ampli®ed or over-expressed in a number of human malignancies, including cancers of the breast, colon and lung (Zeillinger et al., 1989; Prigent and Lemoine, 1992) . Over-expression of ErbB2, in particular, has been associated with a poor prognosis in breast carcinomas (Slamon et al., 1987) and is a possible indicator for the risk of distant metastases (Makar et al., 1990) . Overexpression of the activated form of this receptor when driven by the MMTV promoter in mice leads to rapid induction of mammary gland tumors (Muller et al., 1988) . The wild type form of ErbB2 is also transforming in the murine model, but at a somewhat slower rate (Guy et al., 1992) . Over-expression of the b2c isoform of heregulin has recently been shown to induce mammary gland tumors (Krane and . Transgenic mice bearing this oncogene under control of the MMTV promoter developed adenocarcinomas with an average age of onset of about 357 days after birth in multiparous females. In addition, induction of heregulin in cultured mammary epithelial cells that express the ErbB2 receptor induces an aggressive/invasive transformed morphology (Lupu et al., 1996) .
Given the relevance of apoptosis to tumorigenesis, we recently developed a screen for dominant apoptotic factors (Grimm and Leder, 1997) . In applying this genetic screen we unexpectedly discovered that a novel isoform of heregulin, b2b, is capable of mediating programmed cell death in human kidney cells. Several lines of evidence suggest that this eect is cell autonomous and independent of the extracellular domain of the ligand. Kidney cells transfected with this isoform of heregulin undergo apoptosis, but adjacent non-transfected cells do not. More importantly, 293 cells do not express ErbB3 or ErbB4, the receptors for the neuregulins. Since the eects of speci®c isoforms of a ligand in speci®c tissues are unpredictable and since this family of ligand and receptor have been implicated in both the induction of carcinomas and apoptosis, we wished to assess the apoptotic eects of heregulin b2b and b2c in mammary gland epithelial cells. Herein we show, through examination of cells in culture, as well as tumors in vivo, that heregulin does induce apoptosis in mammary gland epithelia. Furthermore, programmed cell death due to heregulin over-expression appears to occur in a Bcl-2-and caspase-dependent fashion.
Results
Heregulin mediates apoptosis in MCF-7 cells in a manner which can be inhibited by p35
The growth factor heregulin was previously isolated in an in vitro screen of genes which induce apoptosis in a dominant fashion in kidney cells (Grimm and Leder, 1997) . In order to determine if heregulin can induce programmed cell death in breast cancer cells, a series of transient transfections was performed using the MCF-7 cell line. MCF-7 cells display the classic and easily assayed signs of apoptosis upon induction of programmed cell death, namely nuclear condensation and cytoplasmic blebbing (Figure 1a ). All the cDNAs transfected were transcribed by the CMV promoter, which shows a high level of expression in many cell types (Foecking and Hofstetter, 1986) , and assayed approximately 24 h post-transfection, with the death domain-containing gene RIP serving as the positive control (Grimm et al., 1996) .
Previous work has demonstrated a signi®cant dierence in the apoptotic eect of dierent isoforms of heregulin when transfected into human kidney cells (Grimm and Leder, 1997) . Heregulin b2b, which contains an additional 39 amino acids at its Cterminus which are absent in heregulin b2c, induced an almost twofold greater eect than the b2c isoform.
In mammary epithelial cells, however, this dierence is no longer as apparent; both isoforms being quite eective in the induction of apoptosis (Figure 1b) . We furthermore wanted to test the ability of the transmembrane and cytoplasmic domains of heregulin to induce apoptosis. The extracellular domain of heregulin b2b was removed and replaced with the signal peptide of ErbB3 in order to target the resulting protein to the cell membrane. When expressed in breast cancer cells the transmembrane/cytoplasmic domain (construct sig D2 ± 198, Figure 1b ) was sucient to induce apoptosis to a level similar or slightly greater than that seen using the full length construct. This con®rms that the apoptosis seen is not driven by the interaction of the extracellular domain of heregulin with any of the EGFR family members, but rather is cell autonomous as has been previously hypothesized (Grimm and Leder, 1997) .
The viral gene product, p35, has been shown to act as a substrate for, and inhibit the activity of the caspase proteases (Clem et al., 1991; Xue and Horvitz, 1995) . When transfected into MCF-7 cells at a 1 to 2 or 1 to 1 ratio with heregulin b2c, p35 inhibits heregulin-mediated apoptosis in a dose dependent fashion ( Figure 1c ). This indicates that the apoptotic pathway initiated by the over-expression of heregulin is largely, if not entirely, reliant upon the induction of members of the caspase family. The peptide inhibitor zVAD-fmk has also been shown to interfere with caspase function (Longthorne and Williams, 1997) and causes decreased apoptosis when added to MCF-7 cells transfected with heregulin (data not shown).
Stable transfectant epithelial cells apoptose upon induction of heregulin
In order to prove that cell death seen is not due to clonal variation, but rather a result of heregulin induction, we wanted to test stable transfectant cells. Using the muristerone A-inducible system (Invitrogen) we created several stable transfectants of 293 human kidney epithelial cells. Three representative clones were picked which failed to show background promoter activity and produced nearly identical heregulin levels upon induction, as determined by Northern blot analysis (data not shown). The trypan blue exclusion assay was used to assess levels of cell death 24 h postinduction with muristerone A or solvent alone. While the three clones varied somewhat in the level of cell death seen upon induction (Figure 2 ), all were above uninduced control as well as the induced parental line. Heregulin is therefore able to induce cell death when expressed at a more physiologic level in multiple clones. These experiments also demonstrate that heregulin-induced apoptosis is not the result of its activity in combination with the transient transfection procedure.
Epithelial cells from MMTV/heregulin-induced mammary tumors exhibit apoptosis
It has been previously demonstrated that epithelial cells derived from MMTV/heregulin-induced mammary tumors can be propagated in culture (Krane and Leder, 1996) . We wanted to determine if cells cultured from a heregulin-induced tumor retained their ability to undergo apoptosis. Cell lines were harvested while subcon¯uent and subjected to a DNA fragmentation assay ( Figure 3 ). Cell line 9921, established from an MMTV/heregulin tumor and cell line 15963-1, established from an MMTV/heregulin/ MMTV/myc bigenic tumor, both display the clear DNA ladder seen when cells undergo an apoptotic, but not necrotic, death. Surprisingly, these cells did not need to be subjected to serum free media in order to see this eect, as is the case with MMTV/myc overexpressing cells (Amundadottir et al., 1996 and unpublished results) . This suggests that heregulin expression leads to apoptosis even in dividing, transformed cells. These results were con®rmed by Annexin V staining, which binds phosphotidyl-serine and serves as a good marker for early stages of apoptosis. Both fed and serum-starved cells from heregulin-induced tumors showed threefold or higher levels of apoptosis over all other cell lines examined (data not shown).
In vivo apoptosis: mammary gland tumors from MMTV/heregulin mice In order to con®rm the results obtained through tissue culture, we examined tumor tissue for signs of apoptosis. Apoptosis was visualized through the use of terminal deoxynucleotidyl transferase (TdT), which catalyzed the addition of digoxigenin-nucleotides to the 3'-OH ends of DNA breaks (Oncor, Inc). This procedure is highly eective at labeling apoptotic cells, while necrotic cells fail to stain (Gold et al., 1994) . Tumors were harvested from MMTV/heregulin multiparous mice, ®xed, embedded in paran and sectioned to seven microns. Upon staining, these tumors show an extensive, bright, punctate pattern throughout the tumors (Figure 4a ). The¯uorescence was considerably greater in intensity and quantity than seen in other tumors; including tumors initiated by the transgenes MMTV/ras, MMTV/myc and MMTV/neu (Figure 4b ).
Bcl-2 levels are decreased in epithelial cells transfected with heregulin
We have already shown the caspase family to be involved in heregulin-mediated cell death. In order to determine if heregulin acts upstream of the caspase family of cystein proteases, we wanted to determine the levels of the Bcl-2 gene, a known inhibitor of the caspases (Shimizu et al., 1996) , after transfection with heregulin b2b. Two hundred and ninety-three epithelial cells were transfected with CMV/heregulin b2b or a control plasmid, and lysates were collected approximately 24 h later. Western blot analysis was performed with anti-Bcl-2 antibody (Transduction Laboratories). Bcl-2 levels consistently decreased after transfection with heregulin as compared to the control transfection (Figure 5a ). Down-regulation of this anti-apoptotic gene allows for activation of the caspase family which eventually leads to programmed cell death. In order to test the eect of up-regulation of Bcl-2, we transiently transfected the MCF-7 breast cancer epithelial cell line with a CMV/Bcl-2 construct at a 1 to 1 ratio with the heregulin b2b construct. While transfection with heregulin alone allowed for signi®cant apoptosis as shown earlier, co-transfection with Bcl-2 brought the level of apoptosis back to background (Figure 5b ), indicating that Bcl-2 up-regulation is sucient to inhibit the cell death mediated by heregulin b2b. 
Discussion
The human mammary gland epithelial cell line, MCF-7, is a good model system for identifying apoptosis upon over-expression of a gene of interest. MCF-7 cells undergo apoptosis upon induction of exogenous genes (Nickerson et al., 1997; Jaattela et al., 1995) in a manner which involves activation of caspases (Benjamin, 1998). We have found that apoptosing MCF-7 cells display the classic signs of programmed cell death (Bursch et al., 1990) which can easily be identi®ed under phase contrast microscopy. Approximately 20 ± 30% of MCF-7 cells transfected with heregulin undergo apoptosis, demonstrating that heregulin's ability to induce programmed cell death seen in human kidney cells is also present in breast cancer cells. Previous work has shown heregulin to be both mitogenic and dierentiative, depending on the cell line treated (Spivak-Kroizman et al., 1992; Peles et al., 1993) . Heregulin can now be added to a growing list of growth factors which are involved in apoptosis. Such is thought to be the case for the c-myc oncogene, which has also been shown to drive proliferation as well as programmed cell death (Evan et al., 1992) .
It was previously hypothesized that the 39 amino acids of the C-terminus of heregulin b2b played a large role in mediating apoptosis, since the b2c isoform lacking these amino acids failed to induce cell death to a comparable level (Grimm and Leder, 1997) . Our demonstration of apoptotic activity with both isoforms when assessed in mammary epithelial cells indicate that this is a tissue-speci®c property. Just as the various NRG-1 isoforms demonstrate tissue-speci®c interactions with their receptors (reviewed by Burden and Yarden, 1997), so too they appear to have isoform speci®city in the mediation of apoptosis. Their potential role in induction of apoptosis in other tissues in which they are expressed remains an interesting question.
One important dierence between 293 kidney epithelial cells and MCF-7 breast cancer cells is that 293 cells lack ErbB3 and ErbB4 while both receptors are found on MCF-7 cells. The fact that heregulin can induce apoptosis in both cell lines suggests that EGF receptor family status is not a factor in this programmed cell death pathway. We further found that the transmembrane/cytoplasmic segment of heregulin b2b, if targeted to the membrane by a signal sequence, was sucient for induction of apoptosis at a level comparable to that of the full length protein. This supports previous work which demonstrated that in kidney cells the cytoplasmic region was both necessary and sucient to induce apoptosis (Grimm and Leder, 1997; Grimm et al., in press ). This indicates that the programmed cell death associated with heregulin upregulation is both cell autonomous and independent of the EGF receptor signaling pathways.
It has long been established that the mature form of heregulin, namely, its cleaved extracellular domain, is responsible for interactions with the ErbB family of receptors and hence for its proliferative eect. The possible functions, if any, of the cytoplasmic region had previously been unknown. What has been established is that ErbB2, ErbB3 and ErbB4 are endocytosis impaired (Baulida et al., 1996) such that up-regulation of their ligands does not lead to attenuation of the receptors. This can prove dangerous to an organism, since anything which increases heregulin levels will lead to cellular proliferation without any type of feedback inhibition. It can be hypothesized that heregulin plays the role of keeping cell growth in check by inducing apoptosis within the over-expressing cell. This function would be mediated through heregulin's cytoplasmic domain. Furthermore, a functional role for the cytoplasmic domain of heregulin is suggested by its evolutionary conversation (Wen et al., 1994) . It should be noted that another EGFR ligand, TGF-alpha, has been found to interact with two protein kinases through its cytoplasmic tail (Shum et al., 1994) . The possibility that the cytoplasmic region of the various heregulin isoforms interact with proteins involved in apoptosis clearly needs closer examination.
To con®rm that cell death is a property of heregulin expression rather than a clonal variation, we turned to the stable transfection of 293 cells under control of a muristerone A-inducible promoter. Attempts to create stable cell lines of constitutively active heregulin b2b proved futile, possibly due to its apoptotic nature. The stable cell lines underwent apoptosis when heregulin b2b was induced with 2 mM muristerone A. This eect was not reliant upon a block in cellular proliferation since programmed cell death was apparent in serumfed, cycling cells.
Heregulin b2c under the control of the MMTV promoter has been shown to transform mammary gland epithelial cells in mice and give rise to tumor formation (Krane and . We are interested to see if the transformed cells underwent heregulininduced apoptosis or if additional mutations occurred in these cells which allowed for inhibition of programmed cell death. Not only did these cells show higher levels of apoptosis than MCF-7 cells and other mammary gland tumor-derived cell lines, the apoptosis was not dependent upon serum starvation. This is in contrast to work on c-myc transfected ®broblasts, which require arrest of mitogenic function in order to induce apoptosis (Evan et al., 1992) . In order to recapitulate these results in vivo we looked at sections of MMTV/heregulin murine tumors. Once again a much higher level of apoptosis was apparent in heregulin-induced tumors than that seen in myc-, neu-or ras-induced mammary tumors. The lack of signi®cant apoptosis in MMTV/neu tumors is of particular interest since it reinforces the notion that heregulin-induced programmed cell death is independent of its receptors.
Caspases, a family of cysteine proteases which cleave substrates after speci®c aspartic acid residues, are activated in many forms of apoptosis and are a fairly early event in programmed cell death (reviewed by Chinnaiyan and Dixit, 1996; Alnemri et al., 1996) . The viral gene p35 has been shown to inhibit apoptosis by inactivation of the caspase family members through formation of stable caspase-35 complexes (Bump et al., 1995) . The formation of complexes appears to require expression of p35 at amounts comparable to that of the caspases in order to allow eective inhibition. We cotransfected p35 at various ratios to heregulin and found that a dose-dependent inhibition did occur. This indicates that heregulin-mediated apoptosis is similar to many other forms of apoptosis in that it requires the involvement of members of the caspase family. Furthermore, by showing that over-expression of p35 completely blocks heregulin-induced programmed cell death we demonstrate that this apoptosis is mediated exclusively along a caspase pathway. In order to determine if heregulin has an eect earlier in the pathway, we decided to look at Bcl-2 levels after transfection with the b2c isoform. Bcl-2 has been shown to inhibit caspase activation (Shimizu et al., 1996) and its up-regulation in MCF-7 cells has been shown to protect these cells from apoptosis (Mandal and Kumar, 1996) . In addition, inhibition of Bcl-2 has not only been shown to promote apoptosis but to sensitize cells to chemotherapy-induced apoptosis. It can therefore be reasoned that agents which act to down-regulate Bcl-2 expression in breast cancer cells would be interesting from a therapeutic viewpoint. MCF-7 cells which had been transfected with Ha-ras and treated with sodium phenylacetate were shown to have decreased levels of Bcl-2 and have a higher incidence of apoptosis (Adam et al., 1995) . We showed that upon transfection of heregulin b2b, Bcl-2 levels signi®cantly dropped. This would theoretically allow for activation of the caspase family and hence apoptosis. As would be expected, when we cotransfected Bcl-2 at a 1 to 1 ratio with heregulin we no longer see heregulin's apoptotic eect. Whether Bcl-2 down-regulation is a direct action of heregulin overexpression or a result of some other function of heregulin remains to be elucidated.
Materials and methods

Transfections into epithelial cells
MCF-7 cells were transiently transfected using Clonetech's CalPhos Maximizer according to manufacturer's instructions. Plasmids at a ratio of 4.0 mg construct of interest to 0.4 mg marker were added to cells in 60 mm 2 plates (Corning) grown to a density of 40 ± 60% con¯uence. Cells were then incubated 4 h at 378C and 7% CO 2 in DMEM (Gibco) supplemented with 10% FBS, 2% Lglutamate (Gibco) and 1% penicillin/streptomycin (Gibco). The media was then removed and the cells washed twice with 16PBS and incubated 24 ±48 h in supplemented DMEM.
Stable transfections of 293 Vg/R6R kidney epithelial cells (Invitrogen) were also carried out with CalPhos Maximizer. A 6 h transfection was performed using 4 mg DNA into 35 mm 2 plates with cells at approximately 60% con¯uence. The cells were expanded 24 h post-transfection and grown for an additional 24 h in supplemented DMEM, as described above, before changing to selection media containing 400 mg/ ml Zeocin (Invitrogen) and 600 mg/ml G418 (Gibco). Cells were grown with selection media for 9 days before colonies were picked and expanded.
Apoptosis assay
Plates of transfected MCF-7s were ®xed in 4% paraformaldehyde and 2 mM MgCl 2 in 16PBS for 5 min at room temperature. Cells were then washed twice with wash buer (2 mM MgCl 2 , 0.1% NP-40 in 16PBS) and stained overnight at 378C in staining solution (2 mM MgCl 2 , 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 -3H 2 O in 16PBS pH 7.5 and 0.1 mg/ml6-gal (Boehringer Mannheim). After staining, cells were washed with 16PBS and counted with phase contrast microscopy.`Per cent Apoptosis' determined as percentage of stained cells which displayed both (1) nuclear condensation and (2) cytoplasmic blebbing.
Trypan blue exclusion assay
Stable transfectants of 293 Vg/R6R human kidney epithelial cells (Invitrogen) were plated in 35 mm 2 tissue culture plates (Corning) and grown overnight to 30 ± 40% con¯uence in DMEM supplemented with 10% bovine calf serum (Hyclone), 2% L-glutamate and 1% penicillin/streptomycin (Gibco). They were then incubated 24 h with muristerone A (Invitrogen) at a ®nal concentration of 2 mM or solvent alone. Cells were washed twice in 16PBS and gently harvested mechanically before being resuspended in 1 ml PBS and stained with 0.4% trypan blue for 2 min. Trypan blue positive and negative cells were counted using a hemacytometer under phase contrast microscopy. Each condition for each cell line was performed in duplicate and at least 300 cells were assessed for each sample. Cell death was calculated as the percentage of cells that incorporated trypan blue.
DNA fragmentation
Cells to be assayed were grown 24 h in DMEM lacking serum, detached with trypsin and washed once with cold 16PBS. Approximately 1610 7 cells were lysed in cold lysis buer (10 mM Tris-HCl, pH 7.5, 10 mM EDTA, 0.2% Triton X-100) by gentle pipetting. Cells were microfuged for 10 min at 48C and the supernatant transferred to a new tube and phenol/chloroform extracted. DNA was precipitated by addition of 29 ml 5 M NaCl and 980 ml absolute ethanol and overnight incubation at 7208C. After microfuging the pellet is washed once with cold 70% ethanol, resuspended in 15 ml water and treated with 2 ml of 10 mg/ml RNaseA for 30 min at 378C. DNA was then electrophoresed through a 2.0% agarose gel in 16TAE.
In-situ apoptosis analysis
Mouse tumors were dissected, ®xed in Optimal Fix (American Histology Reagent), dehydrated, embedded in paran and sectioned to 7 mm. Apoptosis was then detected using ApoTag-Fluorescein (Oncor, Inc) according to manufacturer's instructions and as previously described (Thiry, 1992) . Cells were viewed under¯uorescent microscopy and given the following grades: 7 for a complete lack of TdT signal, + for less than 5% cell staining with TdT, + for 5 ± 10% staining, ++ for 10 ± 25% staining and +++ for greater than 25% staining.
Western blotting
Cells were incubated with 200 ml RIPA buer (140 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% Na-Deoxycholate) for 20 min at 48C followed by a brief microfuge in order to remove genomic DNA. Lysate is then transferred to a new tube and stored at 7808C in aliquots. Protein concentrations were determined using the BioRad dyebinding microassay with bovine serum albumin standard. A total of 10 or 25 mg protein was electrophoresed through a 15% SDS ± PAGE gel. The proteins were then transferred to a PVDF membrane (Millipore) and blocked overnight in blocking buer (16TBS with 0.1% Tween and 5% non-fat dry milk). Immunodetection was performed using anti-Bcl-2 (Catalog #S82080, Transduction Laboratories) at a dilution of 1 : 500 in the previously described blocking buer. Signals were developed using the enhanced chemiluminescence method (Amersham).
Plasmid constructions
Heregulin b2b, heregulin b2c, RIP and the cytoplasmic domain of heregulin b2b were all subcloned into the pcDNA3 expression vector (Invitrogen) as previously described (Grimm et al., in press ). pSG5-Bcl-2 (Hoang et al., 1994) was digested with EcoRI, yielding a full length Bcl-2 fragment. The Bcl-2 cDNA was also subcloned into the expression vector pcDNA3 and orientation checked via a PstI/XbaI digest. Inducible heregulin b2b was constructed by shuttling the cDNA from pcDNA3 into pIND(SP1) (Invitrogen) with KpnI and NotI sites.
